Zafgen Inc., a Cambridge, MA-based biopharmaceutical company that develops obesity therapeutics, has closed a $21m Series D equity financing.
The round was led by Alta Partners, with participation from existing investors Atlas Venture and Third Rock Ventures.
Founded in 2005 and led by Thomas Hughes, Ph.D., president and chief executive officer, Zafgen focuses on advancing novel therapeutics for patients suffering from severe obesity and obesity-related disorders.
The company intends to use the capital for continued development of its beloranib, which works by targeting a key enzyme called MetAP2 that controls the production and utilization of fatty acids and is currently in phase 2a clinical development. Zafgen, which is expected to release results from this study in June, 2013, licensed beloranib from CKD Pharma.
FinSMEs
04/12/2012